Loading stock data…
Aclaris Therapeutics, Inc. (ACRS)
$6.06-0.11 (-1.78%)
After Hours$6.06+0.00 (+0.00%)· Last close Sep 8
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aclaris Therapeutics, Inc. in the Healthcare sector is trading at $6.06 with a market capitalization of $876M. Wall Street consensus targets $10.18 (11 analysts), implying a +68.0% move over the next 12 months. The stock is currently near its 52-week high of $6.60, remaining 43.3% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +68.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.63M↓ | $2.00M↑ | $1.29M↓ | $3.30M↑ | $1.78M |
| Gross Profit | $176,000↓ | $208,000↑ | -$174,000↓ | $850,000↑ | -$73,000 |
| Operating Income | -$23.94M↓ | -$22.19M↑ | -$22.33M↓ | -$17.05M↓ | -$16.91M |
| Net Income | -$21.50M↓ | -$19.82M↓ | -$19.80M↓ | -$14.61M↑ | -$15.43M |
Peer Comparison
JNJUNHPFE
Fundamentals
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$875.83M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.78
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-60.79%
Volume
Today's trading volume
3.06M
Recent News
Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade
The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of +6.25% and +17.19%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
Aclaris (ACRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
3 Penny Stocks Under $5 Backed by Real Revenue Growth
These three penny stocks under $5 generate real revenue and have catalysts that analysts believe could drive significant upside
Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On
Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the top penny stocks to buy in investors’ stock portfolio. On May 8, Stifel reiterated a Hold rating on Aclaris Therapeutics Inc. (NASDAQ:ACRS) and increased the price target to $4 from $3. The price target hike underscores the research firm’s optimism about the company’s multi-targeting approaches and its […]